Novo Nordisk, GSK and others need to replenish their pipelines to replace drugs coming off patent. In the past, buying a promising biotech required paying a 100% premium. But high interest rates and ...

Market OutlineThe Global Weight Loss Drugs Market is valued at USD 2.88 Billion in 2024 and is projected to reach a value ...

China’s drugmakers are racing to roll out cheaper or more innovative alternatives. Read more at straitstimes.com. Read more ...

Tirzepatide (GIP + GLP-1) has also been shown to reduce cardiovascular risk. In an international trial of 713 adults in nine ...

This FTSE 100 stock could be on the verge of stealing enormous chunks of market share from some of the largest pharmaceutical ...

There's been an all-out push by the drug regulators and media to get every adult and child on Ozempic, a drug which causes temporary weight loss and harms the majority of recipients. Here, two leading ...

Pharma firms are pouncing on opportunity as patents on world’s second-bestselling drug, which goes by brand names Ozempic and ...

Doctors suggest that anybody with a Body mass index of over 30 or greater than 27 is advised to try weight loss drugs.

The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed ...

Detailed price information for Restaurant Brands International (QSR-N) from The Globe and Mail including charting and trades.

Novo Nordisk's steep stock decline has pushed it into deep undervaluation, now trading at attractive multiples below ...